Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06738836 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C]-EDG-7500
A Phase 1 study, sponsored by Edgewise Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT06738836 is a Phase 1 study that has completed, run by Edgewise Therapeutics. The registered enrollment target is 8 participants.
The verdict
NCT06738836, a Phase 1 study, has completed, sponsored by Edgewise Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to: 1. Assess the mass balance (i.e., the cumulative elimination of 14C-related material in urine and feces, compared to the administered amount of radioactive isotope) of \[14C\]-EDG-7500 following a single oral dose of EDG-7500 containing a radioactive tracer, in healthy, adult male subjects. 2. Characterize the pharmacokinetics of EDG-7500 in plasma and of 14C-related material in whole blood, plasma, urine and feces following a single oral dose of EDG-7500 containing a radioactive tracer, in healthy, adult male subjects.
Interventions
- DRUG [14C]-EDG-7500
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2024-12-03 |
| Est. Completion | 2025-01-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06738836
The ClinicalTrials.gov registry entry for NCT06738836 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Edgewise Therapeutics, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [14C]-EDG-7500 is the first listed.
NCT06738836 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06738836 about?
NCT06738836 is a clinical study titled "A Study to Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C]-EDG-7500". The purpose of this study is to: 1. Assess the mass balance (i.e., the cumulative elimination of 14C-related material in urine and feces, compared to the administered amount of radioactive isotope) of \[14C\]-EDG-7500 following a single oral dose of EDG-7500 containing a radioactive tracer, in heal...
What is the current status of trial NCT06738836?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2024-12-03. Estimated completion is 2025-01-17.
What interventions are being tested in trial NCT06738836?
The interventions under investigation include: [14C]-EDG-7500 (DRUG).
Who is sponsoring clinical trial NCT06738836?
This trial is sponsored by Edgewise Therapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.